| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/ 50-200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CIP; CINAP; AD-004; hCINAP; CGI-137 |
| Entrez GeneID | 102157402; |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human AK6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于AK6抗体的3篇参考文献的简要信息(注：文献为示例性内容，实际引用请核实)：
1. **文献名称**：*Adenylate kinase 6 regulates mitotic progression by controlling energy dynamics*
**作者**：Smith J, et al.
**摘要**：研究揭示了AK6通过调控ATP/ADP平衡影响细胞有丝分裂，开发了特异性AK6抗体用于检测其在细胞周期中的表达变化，证实AK6缺失导致染色体分离异常。
2. **文献名称**：*AK6 deficiency promotes metabolic reprogramming in colorectal cancer*
**作者**：Li X, et al.
**摘要**：通过AK6抗体进行免疫组化分析，发现结直肠癌中AK6低表达与糖酵解增强相关，提示AK6可能通过代谢重编程抑制肿瘤进展。
3. **文献名称**：*Structural insights into AK6 catalysis and its inhibition by small molecules*
**作者**：Wang Y, et al.
**摘要**：利用AK6抗体进行蛋白纯化及结构解析，阐明了AK6的催化机制，并筛选出靶向AK6的小分子抑制剂，为相关疾病治疗提供新策略。
*注：以上文献信息为模拟示例，实际研究需查阅具体数据库(如PubMed)获取。*
The AK6 antibody targets Aurora Kinase A (AURKA), a serine/threonine kinase critical for regulating mitotic progression, spindle assembly, and chromosome segregation. Aurora Kinase A is part of the Aurora kinase family, which includes Aurora B and C, and is predominantly expressed during the G2/M phase of the cell cycle. Dysregulation of Aurora A is linked to genomic instability, tumorigenesis, and poor prognosis in cancers such as breast, ovarian, and colorectal. Its overexpression promotes uncontrolled proliferation, metastasis, and resistance to chemotherapy.
AK6 antibodies are valuable tools in research and diagnostics, enabling detection of Aurora A expression levels in tissues or cell lines via techniques like Western blotting, immunohistochemistry, or flow cytometry. They also aid in studying Aurora A's functional roles in cell cycle control and its interaction with substrates (e.g., TPX2. BRCA1). In therapeutic contexts, Aurora A inhibitors are explored as anticancer agents, and AK6 antibodies may assist in validating drug efficacy or monitoring target engagement. However, challenges remain, including potential cross-reactivity with other Aurora kinases or isoforms. Ongoing research aims to refine antibody specificity and explore clinical applications, such as companion diagnostics for Aurora A-targeted therapies.
×
